An interventional study of Dexmedetomidine Intravenous Infusion in Septic Shock, Sepsis and Critical Illness, sponsored by First Affiliated Hospital of Wannan Medical College. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by First Affiliated Hospital of Wannan Medical College · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing dexmedetomidine in Shock, Septic — 4 open to participants now, 4 under way, 1 of them phase 3. Dexmedetomidine · Shock, Septic.
Among the 11 studies testing dexmedetomidine in Shock, Septic, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 with no phase, and was the 11th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →4 of the 11 studies testing dexmedetomidine in Shock, Septic are open now, in 3 countries. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–90
Hospices Civils de Lyon · Sites in France
Ages 18+
Sichuan Academy of Medical Sciences
Ages 18+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 40 across the 11 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Wannan Medical College is the lead sponsor of 37 studies on the registry; 34 are open to participants now.
First Affiliated Hospital of Wannan Medical College has 8 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing dexmedetomidine in Shock, Septic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective, multicenter, single-arm, open-label interventional pilot study aims to evaluate the short-term physiological effects of intravenous dexmedetomidine on sublingual microcirculation and vascular-waterfall parameters in adult patients with septic shock.
Eligible patients will have septic shock according to Sepsis-3 criteria, require norepinephrine support after adequate fluid resuscitation, receive invasive mechanical ventilation, and have PiCCO-based hemodynamic monitoring available before dexmedetomidine initiation. After baseline assessment, participants will receive intravenous dexmedetomidine according to the study protocol. Dexmedetomidine will be administered as a continuous intravenous infusion at 0.2-0.7 µg/kg/hour without a loading dose. The infusion rate may be adjusted according to the target sedation level, hemodynamic status, and adverse effects.
Sublingual microcirculatory variables, including microvascular flow index, perfused vessel density, proportion of perfused vessels, and heterogeneity index, as well as vascular-waterfall parameters, including estimated critical closing pressure, estimated mean systemic filling pressure, and the Pcc-Pmsf gradient, will be measured at baseline, 3 hours, and 6 hours after initiation of dexmedetomidine. Systemic hemodynamic, perfusion, vasopressor, PiCCO-derived, sedation-related, and safety outcomes will also be collected.
The primary objective is to characterize immediate changes in sublingual microcirculation and vascular-waterfall physiology after dexmedetomidine administration and to provide preliminary data for future controlled studies.
Septic shock is characterized by profound circulatory dysfunction involving both the macrocirculation and the microcirculation. Although conventional resuscitation targets such as mean arterial pressure, cardiac output, and serum lactate are widely used, microcirculatory alterations may persist despite apparent stabilization of systemic hemodynamics. Direct evaluation of sublingual microcirculation may therefore provide additional physiological information in patients with septic shock.
Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist commonly used for sedation in critically ill patients. Compared with traditional sedatives, dexmedetomidine provides cooperative sedation with limited respiratory depression and may modulate sympathetic tone, inflammation, endothelial function, and regional perfusion. However, dexmedetomidine may also cause bradycardia, hypotension, and changes in vascular tone, which may influence systemic hemodynamics and microcirculatory perfusion. Its immediate effects on directly visualized sublingual microcirculation and vascular-waterfall physiology in patients with septic shock remain insufficiently characterized.
The vascular-waterfall phenomenon refers to the concept that tissue perfusion is influenced not only by arterial and venous pressures but also by the relationship between upstream pressure, critical closing pressure, and mean systemic filling pressure. In septic shock, changes in vascular tone, vasopressor exposure, stressed blood volume, venous return, and cardiac output may alter the effective pressure gradient for tissue perfusion. Evaluation of vascular-waterfall variables together with direct sublingual microcirculatory imaging may provide mechanistic insight into the physiological effects of dexmedetomidine beyond conventional macrocirculatory variables.
This is a prospective, multicenter, single-arm, open-label, interventional pilot physiological study conducted in adult intensive care unit patients with septic shock. Patients will be screened after initial hemodynamic optimization. Eligible patients must have septic shock according to Sepsis-3 criteria, ongoing norepinephrine support, invasive mechanical ventilation with a clinical need for sedation, and PiCCO-based hemodynamic monitoring available before dexmedetomidine initiation. Patients with contraindications to dexmedetomidine, severe bradycardia, high-grade atrioventricular block without a pacemaker, severe uncontrolled arrhythmia, severe hemodynamic instability judged unsuitable for dexmedetomidine, or conditions interfering with sublingual microcirculatory imaging will be excluded.
After informed consent is obtained, baseline measurements will be performed immediately before dexmedetomidine administration. Dexmedetomidine will be administered as a continuous intravenous infusion at 0.2-0.7 µg/kg/hour without a loading dose. The dose may be titrated by the treating physician according to the target sedation level, hemodynamic status, heart rate, vasopressor requirement, and adverse effects. The target sedation level will generally be light-to-moderate sedation according to local ICU practice, such as a Richmond Agitation-Sedation Scale score between -2 and 0, unless otherwise clinically indicated. Dose reduction, temporary interruption, or discontinuation will be permitted for safety reasons, including clinically significant hypotension, bradycardia, new-onset or worsening arrhythmia, high-grade atrioventricular block, increased vasopressor requirement, suspected myocardial ischemia, or other clinically significant adverse events.
Study assessments will be performed at baseline, 3 hours, and 6 hours after initiation of dexmedetomidine. Sublingual microcirculatory imaging will be used to assess microvascular flow index, perfused vessel density, proportion of perfused vessels, and microcirculatory heterogeneity index. Vascular-waterfall related variables will include estimated critical closing pressure, estimated mean systemic filling pressure, and the Pcc-Pmsf gradient. Systemic hemodynamic and perfusion variables, including heart rate, mean arterial pressure, cardiac index, norepinephrine dose, arterial lactate, urine output, capillary refill time, Richmond Agitation-Sedation Scale score, and PiCCO-derived variables, will also be recorded.
Approximately 20 patients will be enrolled to assess feasibility and generate preliminary estimates of physiological changes after dexmedetomidine administration. The main analyses will describe changes from baseline in sublingual microcirculatory and vascular-waterfall parameters over the 6-hour observation period. Safety events, especially bradycardia, hypotension, high-grade atrioventricular block, and increased vasopressor requirement, will be summarized descriptively to inform the design of subsequent controlled studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with septic shock receiving invasive mechanical ventilation, norepinephrine support, and PiCCO-based hemodynamic monitoring after initial resuscitation will receive intravenous dexmedetomidine. Sublingual microcirculatory, vascular-waterfall, PiCCO-derived, macrocirculatory, perfusion, sedation-related, and safety variables will be assessed at baseline, 3 hours, and 6 hours after dexmedetomidine initiation.
Drug: Dexmedetomidine Intravenous Infusion
Dexmedetomidine will be administered as a continuous intravenous infusion at 0.2-0.7 µg/kg/hour without a loading dose. The infusion rate may be adjusted according to the target sedation level, heart rate, mean arterial pressure, vasopressor requirement, PiCCO-derived hemodynamic variables, and adverse effects. Dose reduction, temporary interruption, or discontinuation is permitted for safety reasons, including clinically significant hypotension, bradycardia, new-onset or worsening arrhythmia, high-grade atrioventricular block, suspected myocardial ischemia, increased vasopressor requirement, or other clinically significant adverse events. The actual dose, infusion duration, and reasons for dose adjustment or discontinuation will be recorded.
Also known as: Dexmedetomidine hydrochloride, Dex
Change From Baseline in Pcc-Pmsf Gradient
The vascular-waterfall pressure gradient will be calculated as the difference between estimated critical closing pressure and estimated mean systemic filling pressure. The outcome is the change in Pcc-Pmsf from baseline to 3 and 6 hours after dexmedetomidine initiation.
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Sublingual Microvascular Flow Index
Microvascular flow index will be assessed using sublingual microcirculatory imaging. Three to five sublingual video fields will be recorded at each time point, and MFI will be calculated according to standard microcirculatory scoring methods. The outcome is the change in MFI from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Perfused Vessel Density
Perfused vessel density will be measured from sublingual microcirculatory images. The outcome is the change in PVD from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Proportion of Perfused Vessels
Proportion of perfused vessels will be measured from sublingual microcirculatory images. The outcome is the change in PPV from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine.
Change From Baseline in Microcirculatory Heterogeneity Index
Microcirculatory heterogeneity index will be calculated from sublingual microcirculatory measurements. The outcome is the change in HI from baseline to 3 and 6 hours after dexmedetomidine initiation.
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Estimated Critical Closing Pressure
Estimated critical closing pressure will be calculated using predefined hemodynamic methods based on arterial pressure waveform-derived parameters and PiCCO-based cardiac output measurements. The outcome is the change in Pcc from baseline to 3 and 6 hours after dexmedetomidine initiation.
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Estimated Mean Systemic Filling Pressure
Estimated mean systemic filling pressure will be calculated using predefined hemodynamic methods based on PiCCO-derived cardiac output and systemic vascular resistance-related variables. The outcome is the change in Pmsf from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Mean Arterial Pressure
Mean arterial pressure will be recorded from invasive arterial monitoring at each study time point. The outcome is the change in MAP from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Heart Rate
Heart rate will be recorded from bedside monitoring at each study time point. The outcome is the change in heart rate from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Cardiac Index
Cardiac index will be measured using PiCCO-based hemodynamic monitoring. The outcome is the change in cardiac index from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Norepinephrine Dose
Norepinephrine dose will be recorded in µg/kg/min at each study time point. The outcome is the change in norepinephrine dose from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Arterial Lactate
Arterial lactate concentration will be measured according to routine clinical practice. The outcome is the change in lactate from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Capillary Refill Time
Capillary refill time will be assessed according to local clinical practice. The outcome is the change in capillary refill time from baseline to 3 and 6 hours after dexmedetomidine initiation
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine
Change From Baseline in Richmond Agitation-Sedation Scale Score
Sedation depth will be assessed using the Richmond Agitation-Sedation Scale. The outcome is the change in RASS score from baseline to 3 and 6 hours after dexmedetomidine initiation.
Time frame: Baseline, 3 hours, and 6 hours after initiation of dexmedetomidine.
Incidence of Clinically Significant Bradycardia
Clinically significant bradycardia will be recorded during the observation period. Bradycardia is defined as heart rate less than 50 beats per minute, or any decrease in heart rate requiring dose reduction, temporary interruption, discontinuation of dexmedetomidine, atropine administration, pacing, or other clinical intervention
Time frame: From initiation of dexmedetomidine to 6 hours after initiation.
Incidence of Clinically Significant Hypotension
Clinically significant hypotension will be recorded during the observation period. Hypotension is defined as mean arterial pressure less than 65 mmHg, or any decrease in blood pressure requiring fluid bolus, escalation of vasopressor or inotropic support, dose reduction, temporary interruption, or discontinuation of dexmedetomidine
Time frame: From initiation of dexmedetomidine to 6 hours after initiation.
ICU Length of Stay
Number of days from ICU admission to ICU discharge.
Time frame: From ICU admission to ICU discharge, assessed up to 28 days after enrollment.
28-Day Mortality
All-cause mortality within 28 days after enrollment.
Time frame: 28 days after enrollment.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.
Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 16 months is below that.
Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
First Affiliated Hospital of Wannan Medical College